CL2021000627A1 - Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular - Google Patents

Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular

Info

Publication number
CL2021000627A1
CL2021000627A1 CL2021000627A CL2021000627A CL2021000627A1 CL 2021000627 A1 CL2021000627 A1 CL 2021000627A1 CL 2021000627 A CL2021000627 A CL 2021000627A CL 2021000627 A CL2021000627 A CL 2021000627A CL 2021000627 A1 CL2021000627 A1 CL 2021000627A1
Authority
CL
Chile
Prior art keywords
joint
treatment
pharmaceutical compositions
compositions suitable
joint pain
Prior art date
Application number
CL2021000627A
Other languages
English (en)
Inventor
Yun-Long Tseng
Sheue-Fang Shih
Po-Chun Chang
Lo Chang
Original Assignee
Tlc Biopharmaceuticals Inc
Taiwan Liposome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tlc Biopharmaceuticals Inc, Taiwan Liposome Co Ltd filed Critical Tlc Biopharmaceuticals Inc
Publication of CL2021000627A1 publication Critical patent/CL2021000627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se relaciona con una composición farmacéutica para el tratamiento del dolor articular. La composición contiene una mezcla lipídica, que comprende uno o más fosfolípidos, y una cantidad efectiva de un agente terapéutico, o alguna de sus sales farmacéuticamente aceptables; donde la cantidad total de fosfolípidos en dicha composición es de aproximadamente 20 mM a aproximadamente 150 mM, opcionalmente de 70 mM a 110 mM. Además, se proporciona el uso de la composición farmacéutica en el tratamiento del dolor articular por medio de una inyección articular.
CL2021000627A 2018-09-16 2021-03-15 Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular CL2021000627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16

Publications (1)

Publication Number Publication Date
CL2021000627A1 true CL2021000627A1 (es) 2021-09-10

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000627A CL2021000627A1 (es) 2018-09-16 2021-03-15 Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular

Country Status (15)

Country Link
US (1) US20210338688A1 (es)
EP (1) EP3849522A1 (es)
JP (1) JP2022500364A (es)
KR (1) KR20210060559A (es)
CN (1) CN112702993A (es)
AU (1) AU2019339528A1 (es)
BR (1) BR112021004880A2 (es)
CA (1) CA3112234A1 (es)
CL (1) CL2021000627A1 (es)
IL (1) IL281513A (es)
MX (1) MX2021003030A (es)
SG (1) SG11202102400PA (es)
TW (1) TWI843751B (es)
WO (1) WO2020056399A1 (es)
ZA (1) ZA202101688B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537474A (ja) 2020-08-05 2023-09-01 ティーエルシー バイオファーマシューティカルズ、インク． 疼痛制御のための関節内コルチコステロイドの医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
DK2854769T3 (da) * 2012-07-05 2023-06-26 Taiwan Liposome Co Ltd Fremgangsmåder til behandling af artritis

Also Published As

Publication number Publication date
AU2019339528A1 (en) 2021-04-15
MX2021003030A (es) 2021-05-27
JP2022500364A (ja) 2022-01-04
TWI843751B (zh) 2024-06-01
SG11202102400PA (en) 2021-04-29
CA3112234A1 (en) 2020-03-19
US20210338688A1 (en) 2021-11-04
BR112021004880A2 (pt) 2021-06-01
CN112702993A (zh) 2021-04-23
WO2020056399A1 (en) 2020-03-19
EP3849522A1 (en) 2021-07-21
TW202023569A (zh) 2020-07-01
ZA202101688B (en) 2024-06-26
KR20210060559A (ko) 2021-05-26
IL281513A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR098989A1 (es) Composiciones farmacéuticas que comprenden azd9291
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
DOP2022000053A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
DOP2019000070A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
UY38964A (es) Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
DOP2019000071A (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
CL2021000282A1 (es) Inhibidores de ckd8/19
CO2023009085A2 (es) Pauta posológica de levodopa
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos
CL2020002398A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR100153A1 (es) Medicamento
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos